β₂ Adrenergic Receptor Gene Arg16Gly Polymorphism is Associated with Therapeutic Efficacy of Benazepril on Essential Hypertension in Chinese

Abstract

Background: There is considerable variability in individual response to antihypertensive agents. The reason for this is not known, but may be related to individual genetic variability. This study examined whether the therapeutic efficacy of benazepril on essential hypertension is modified by β₂ adrenergic receptor gene (ADRB2) Arg16Gly (R16G) polymorphism. Methods and Results: We conducted a family‐based study of 321 and 610 hypertensive subjects from Yuexi and Huoqiu Counties of Anhui, China, respectively. Both systolic and diastolic blood pressures (SBP and DBP) before and after a 15‐day benazepril treatment were measured. ADRB2 R16G genotypes were determined for all subjects. ADRB2 G16 allele frequency was found to be 41.0% and. 47.4% in Huoqiu and Yuexi, respectively. In Yuexi family‐based association test (FBAT) revealed that the G16 allele was associated with a greater DBP decrease in response to a 15‐day benazepril treatment (Z = 2.12, P = 0.03), and the data were consistent with a dominant inheritance model. A similar trend was observed in Huoqiu Chinese, but the magnitudes of effects were smaller and did not reach statistical significance. The FBAT results were further confirmed by using a generalized estimating equation model. Conclusion: Our family‐based study provided the first evidence that ADRB2 R16G polymorphism may play an important role in DBP response to benazepril treatment, although the magnitude of the effect appears to be modified by other risk factors such as plasma lipid and glucose profiles.

• ADRB2 gene
• Gene polymorphism
• Benazepril
• Blood pressure
• Pharmacogenetics